About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Schizophrenia Clinical Trials in Chicago | 193 Studies

Clinical Trials SchizophreniaChicago

Schizophrenia Clinical Trials in Chicago

Find 193 clinical trials for schizophrenia near Chicago, Illinois. Connect with research centers in your area.

All Schizophrenia trials nationwide All trials in Chicago

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 101-120 of 193 trials

CompletedStudy to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderThis study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in…NCT03187769·Little Rock, Arkansas and 56 others

Schizophrenia Trials in Other Cities

New York Los Angeles Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

RecruitingStudy to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaThis is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the…NCT07363577·Bentonville, Arkansas and 12 others

RecruitingStudy to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderTo compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapineNCT05303064·Dothan, Alabama and 46 others

CompletedOpen-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot AripiprazoleThe purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of…NCT01432444·Dothan, Alabama and 123 others

RecruitingA Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaThe purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments.NCT07615426·Garden Grove, California and 7 others

CompletedA Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaThe primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.NCT02873208·Little Rock, Arkansas and 44 others

CompletedA Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With SchizophreniaThe purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of…NCT01529515·Little Rock, Arkansas and 52 others

RecruitingTransition Care for FEPThis study is testing a new approach to help people with first episode psychosis transition successfully from the hospital to outpatient mental health care.NCT07713849·Chicago, Illinois and 1 other

CompletedA Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery…NCT03745820·Bentonville, Arkansas and 59 others

CompletedA Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaThis is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of…NCT05227703·Bentonville, Arkansas and 25 others

CompletedStudy to Evaluate the Efficacy and Safety of GSK239512 in SchizophreniaThis study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophreniaNCT01009060·Garden Grove, California and 14 others

CompletedA Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaThis is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.NCT01678755·Chino, California and 19 others

CompletedRandomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia PatientsThe purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with placebo in the treatment of patients with schizophrenia.NCT02109562·Little Rock, Arkansas and 31 others

CompletedEffect of Lu AF35700 in Patients With Treatment-resistant SchizophreniaTo evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)NCT02717195·Bellflower, California and 146 others

Completed7-week Study With CT-155 in People With SchizophreniaCT-155 is a novel prescription digital therapeutic (PDT) to treat schizophreniaNCT05486312·Culver City, California and 9 others

CompletedStudy to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of SchizophreniaMIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult…NCT03397134·Rogers, Arkansas and 38 others

CompletedOlanzapine Versus An Active Comparator in the Treatment of SchizophreniaThe purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophreniaNCT00036088·El Centro, California and 59 others

CompletedRandomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaThis is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with…NCT06179108·Bentonville, Arkansas and 24 others

CompletedThe Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I DisorderOlanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder.NCT00044187·El Centro, California and 15 others

TerminatedStudy Evaluating Bifeprunox in Patients With Schizophrenia.An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.NCT00366327·Little Rock, Arkansas and 81 others

PreviousPage 6 of 10Next

Other Conditions in Chicago

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia